Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 57 - 61
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052111s57
Publié en ligne 15 novembre 2005
  1. Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med 1973; 289 : 9–14. [Google Scholar]
  2. Desnick RJ, Dean KJ, Grabowski G, et al. Enzyme therapy in Fabry disease : differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-agalsidase A isozymes. Proc Natl Acad Sci USA 1979; 76 : 5326–30. [Google Scholar]
  3. Ioannou YA, Bishop DF, Desnick RJ. Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J Cell Biol 1992; 119 : 1137–50. [Google Scholar]
  4. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease : preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001; 68 : 14–25. [Google Scholar]
  5. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease : pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68 : 711–22. [Google Scholar]
  6. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase replacement therapy in Fabry’s disease. N Engl J Med 2001; 345 : 9–16. [Google Scholar]
  7. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62 : 1933–46. [Google Scholar]
  8. Thurberg BL, Randolph Byers H, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004; 122 : 900–8. [Google Scholar]
  9. Wilcox W, Banikazemi M, Guffon N, et al. Long-term safety and efficacity of enzyme replacement therapy Fabry disease. Am J Hum Genet 2004; 75 : 65–74. [Google Scholar]
  10. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease : influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81 : 122–38. [Google Scholar]
  11. Kowey PR, Dickson TZ, Zhang Z, et al. Losartan and end-organ protection : lessons from the RENAAL study. Clin Cardiol 2005; 28 : 136–42. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.